site stats

Dyne therapeutics investors

WebMar 7, 2024 · WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on … WebApr 11, 2024 · Finally, Tower Research Capital LLC TRC boosted its stake in Dyne Therapeutics by 425.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,582 shares of the company's stock valued at $122,000 after buying an additional 7,757 shares in the last quarter. Institutional investors own 85.50% of the company's stock. …

Dyne Therapeutics Announces Presentations on its DM1 and …

WebApr 11, 2024 · Finally, Tower Research Capital LLC TRC boosted its stake in Dyne Therapeutics by 425.0% in the third quarter. Tower Research Capital LLC TRC now … WebMar 20, 2024 · About Dyne Therapeutics. ... Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 . jordan baptist church in maryland https://sister2sisterlv.org

We

WebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. WebNov 2, 2024 · About Dyne Therapeutics. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for … WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). jordan basketball shoes for women

2024-03-20 NDAQ:DYN Press Release Dyne Therapeutics Inc.

Category:Stock Market FinancialContent Business Page

Tags:Dyne therapeutics investors

Dyne therapeutics investors

Dyne Therapeutics Announces Presentations on its DM1 and

WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of 400,449. WebMar 7, 2024 · WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual …

Dyne therapeutics investors

Did you know?

WebMay 15, 2024 · May 14, 2024 8:16 PM ET Dyne Therapeutics, Inc. (DYN) SA Transcripts. 135.02K Follower s. The following slide deck was published by Dyne Therapeutics, Inc. … Web10 rows · Dyne Therapeutics has raised a total of $333M in funding over 4 rounds. Their latest funding was ...

WebApr 13, 2024 · Aurinia Pharmaceuticals Inc (AUPH) stock is trading at $11.20 as of 3:06 PM on Thursday, Apr 13, a rise of $0.16, or 1.5% from the previous closing price of $11.03. The stock has traded between $11.04 and $11.49 so far today. Volume today is less active than usual. So far 1,641,446 shares have traded compared to average volume of 3,314,036 … WebMar 26, 2024 · When Dyne Therapeutics last reported its balance sheet in December 2024, it had zero debt and cash worth US$256m. In the last year, its cash burn was US$157m. Therefore, from December 2024 it had roughly 20 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces …

WebMar 20, 2024 · The Investor Relations website contains information about Dyne Therapeutics, Inc.'s business for stockholders, potential investors, and financial … Mar 10, 2024: 8-K: Report of unscheduled material events or corporate event. … The Investor Relations website contains information about Dyne Therapeutics, … Amy Reilly. Senior Vice President, Corporate Communications & Investor … The Investor Relations website contains information about Dyne Therapeutics, … WebApr 11, 2024 · A high-level overview of Dyne Therapeutics, Inc. (DYN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

WebNov 2, 2024 · Dyne Therapeutics, Inc. WALTHAM, Mass., Nov. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life ...

WebChief Commercial Officer. Christopher S. Billis joined MC2 Therapeutics as Chief Commercial Officer from his most recent position as Head of Marketing, Bayer … jordan batchelorWebAug 10, 2024 · Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. Contacts Stephanie Simon Ten Bridge Communications (617 ... how to integrate fingerprint scanner in phphow to integrate firebase in flutterWebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... Investors Dyne ... how to integrate facebook sdk unityWeb19 hours ago · As an investor, you want to buy stocks with the highest probability of success. ... Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of ... how to integrate facebook on clickfunnelsWebFeb 27, 2024 · The 86 rating InvestorsObserver gives to Dyne Therapeutics Inc stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, DYN’s 86 overall rating means the stock scores better than 86 percent of all stocks. jordan bathroom productsWebMay 15, 2024 · May 14, 2024 8:16 PM ET Dyne Therapeutics, Inc. (DYN) SA Transcripts. 135.02K Follower s. The following slide deck was published by Dyne Therapeutics, Inc. in conjunction with this event. View as ... jordan bathroom shower curtain